Evaluation of the Efficiency and Safety of Stereotactic Body Radiation Therapy Combined With PD-1 Antibody in the Treatment of Unresectable Locally Recurrent Rectal Cancer: A Prospective, Multicenter, Single-Arm, Open Label, Phase II Study
Latest Information Update: 28 Jan 2025
Price :
$35 *
At a glance
- Drugs Antineoplastics (Primary) ; Fluorouracil (Primary) ; Sintilimab (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms SPARKLE
- 22 Jan 2025 Status changed from not yet recruiting to recruiting.
- 16 Jan 2025 New trial record